IN THE CLAIMS:

Please amend the claims according to 37 C.F.R. 1.121 (see also the accompanying "marked up" version pursuant to 37 C.F.R. 1.121):

1. (Amended) A pharmaceutical composition comprising as an active ingredient a recombinant polyclonal antibody capable of reacting with or binding to an allergen, together with one or more pharmaceutically acceptable excipients.

6. (Twice amended) A pharmaceutical composition according to claim 1, comprising at least one pharmaceutically acceptable excipient capable of effecting topical application of said recombinant polyclonal antibody.

8. (Amended) A pharmaceutical composition according to claim 7, wherein the respiratory tract is selected from nasal, oral, pharyngeal, bronchial, or alveolar mucosa.

13. (Twice amended) A pharmaceutical composition according to claim 1, wherein the allergen is an allergen of house dust mites, dander from cat, dander from dog, dander from horse, tree pollen, grass pollen, or fungi.

14. (Twice amended) A pharmaceutical composition according to claim 1, comprising the recombinant polyclonal antibody in an amount in the range of 1μg to 1g per unit dosage form.

23. (Twice amended) A method of preventing or treating an allergic reaction in a patient in need thereof, which method comprises administering to the patient a composition comprising a polyclonal antibody preparation capable of reacting with or binding to an allergen to which the patient has shown or is predisposed to develop an allergic reaction, and a pharmaceutically acceptable excipient,

wherein the composition comprises a sufficient amount of polyclonal antibody preparation to prevent or treat the allergic reaction.

24. (Twice amended) A method of inducing tolerance to an allergen in a patient who would be likely to show an allergic reaction to the allergen if untreated, which method comprises administering to the patient a composition comprising a polyclonal antibody preparation capable of reacting with or binding to the allergen and induce tolerance to the allergen in the patient, and a pharmaceutically acceptable excipient,

wherein the composition comprises a sufficient amount of polyclonal antibody preparation to induce tolerance to the allergen in the patient.

Please add the following new claims:

25. (New) A method according to claim 23, wherein the polyclonal antibody preparation comprises a recombinant polyclonal antibody.

26. (New) A method according to claim 23, wherein the composition is free of the allergen to which the antibody is reactive or binds.

27. (New) A method according to claim 23, wherein said pharmaceutically acceptable excipient is capable of effecting topical application of said polyclonal antibody preparation.

28. (New) A method according to claim 23, wherein said administration comprises topical application to the oropharynx, nasal cavity, respiratory tract, gastrointestinal tract, conjunctival mucosa, vagina, or urogenital mucosa, or dermal application.

29. (New) A method according to claim 23, wherein said composition is provided as a solution, a dispersion, a powder, or in the form of microspheres.

30. (New) A method according to claim 23, wherein the polyclonal antibody preparation comprises a recombinant polyclonal antibody generated by phage display technology.

31. (New) A method according to claim 23, wherein the allergen is an allergen selected from the group consisting of house dust mites, dander from cat, dander from dog, dander from horse, tree pollen, grass pollen, and fungi.

32. (New) A method according to claim 23, wherein the amount of polyclonal antibody preparation is in the range of 1μg to 1g.

33. (New) A method according to claim 23, wherein the amount of polyclonal antibody preparation is in the range of 2-500 μg.

34. (New) A method according to claim 23, wherein the amount of polyclonal antibody preparation is in the range of 5-50 μg.